The interventions under study are targeted on the primary pathophysiological processes of PD, such as α-synuclein aggregation, or the glucocerebrosidase (GBA) or leucine-rich repeat kinase 2 (LRRK2) pathways, which start years before clinical symptoms appear [2]. This evidence concerns the gene LRRK2 and Parkinson disease.